Sponsor Interview: Miltenyi Biotec

What excites you most about partnering with and participating in the 7th TCR Based Therapies Summit this year?

We partnered with Hanson Wade for last year’s TCR Summit, which proved to be a highly successful and engaging event. We are excited to participate again this year and look forward to strengthening our partnerships with leading immune-oncology scientists, as well as connecting with additional stakeholders working to advance TCR-based therapies. We also anticipate many fruitful discussions around the latest developments in the field and are pleased to present our solutions to support the progress of TCR-based innovation.

 

The field is evolving rapidly. What conversations are you most looking forward to having with fellow innovators at the event?

We are keen to better understand both recurring and emerging challenges associated with TCR-based therapeutics in oncology, and to explore how we, as a biotechnology company, can help address and overcome these limitations through our technologies and long-standing expertise in immunotherapy

 

What makes this year’s TCR-Based Therapies Summit particularly timely for this community?

TCR-based therapeutic approaches are gaining increasing importance in oncology because they enable the targeting of intracellular antigens, significantly expanding the range of treatable cancer targets. With rapid advances in antigen discovery and TCR engineering, these strategies are emerging as a promising next generation of immunotherapies. In this evolving field, conferences such as the TCR Summit play a crucial role by enabling scientific exchange, fostering collaboration, and accelerating progress in TCR-based therapies

 

What do you see as the biggest hurdle in bringing potent and safe TCR therapies successfully into the clinic and onward to commercial viability?

One of the biggest hurdles is ensuring both safety and specificity, particularly minimizing off-target recognition and cross-reactivity with healthy tissues. In addition, challenges around target selection, patient HLA restriction, and scalable manufacturing continue to impact the broad clinical and commercial viability of TCR-based therapies.

 

Miltenyi Biotec is going to be presenting at this year’s meeting, what will you be sharing and why are you excited for what your work means for the field?

Our presentation will focus on a combinatorial T cell therapy strategy that integrates CAR‑T and TCR‑T approaches to address the challenges of solid tumors. We will highlight how targeted viral engineering, including Paramyxovirus‑based pseudotyping, enables more selective and efficient transduction of relevant T cell subsets, creating a strong foundation for combination strategies. Together, these approaches are designed to enhance tumor recognition and killing, and we are excited to share preclinical data that illustrate their potential to improve the effectiveness of next‑generation T cell therapies.

 

Looking ahead, how do you see this community’s work reshaping the landscape over the next decade, and what role do partnerships play in accelerating that future?

Addressing the challenges associated with TCR-based therapeutics requires close collaboration across academia, biotechnology companies, and industry partners. Strong partnerships within the community are essential to accelerate scientific progress, translate discoveries into clinical applications, and overcome existing barriers. Through continued collaboration and knowledge exchange, the field can advance toward more patient-centered, accessible, and effective cancer treatments compared with conventional therapeutic approaches.